SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is currently experiencing high volatility, with the community actively debating whether it remains a viable meme coin leader or is merely a stagnant asset, all while market participants closely watch Bitcoin's price action for potential momentum shifts. Discussions are heavily fueled by speculative hopes for a breakthrough rally and frustration among long-term holders waiting for a sustained upward trend.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing heavy social media volume as traders debate whether the semiconductor sector's record-breaking win streak is nearing a parabolic peak or represents an unbreakable AI-driven super cycle. Community members are actively sharing their high-conviction positions and frustration over the instrument's significant decay, while others continue to debate the timing of a potential sector-wide pullback.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

The semiconductor sector is currently experiencing historic, parabolic growth, fueling intense community debate over whether this represents a sustainable AI-driven super cycle or a bubble nearing a blow-off top. Investors are actively watching earnings reports and geopolitical tensions as key catalysts, with high-conviction bulls adding to leveraged positions while some market observers warn that extreme technical indicators suggest an imminent pullback.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors aggressively accumulate in anticipation of upcoming announcements and the project's featured presence at the XRP Las Vegas conference. Community sentiment remains polarized, with long-term holders emphasizing patience and potential utility-driven growth, while others debate the impact of volatility and market speculation.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as the company's Phase 3 readout for its gene-editing therapy approaches, fueling intense speculation about a potential short squeeze given the high level of short interest. The community is actively debating the reliability of clinical trial designs and the broader implications for the gene-editing sector, with many participants watching closely for how the impending data will move the stock.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy (XE) is surging following its highly anticipated IPO, with investors heavily focused on its strategic backing from Amazon and its potential role in powering AI data centers. The community is actively debating the stock's valuation relative to SMR peers while tracking high institutional interest and strong demand that exceeded initial expectations.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community doubles down on the project, pushing back against recent volatility and negative sentiment by highlighting ongoing development and a long-term shift toward utility and AI-focused business management. Holders are actively discussing their commitment to the project, emphasizing the importance of community perseverance and a 'build-it' mentality while dismissing concerns regarding project viability.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins (PENGU) is generating buzz as investors monitor its transition from an NFT-based brand to a "phygital" ecosystem with physical toy sales and potential retail expansion. The community remains divided between long-term holders accumulating shares amidst price volatility and skeptics comparing its recent performance to other speculative meme coins.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently capturing significant community attention as traders closely monitor technical resistance levels and look for a breakthrough above the key four-cent barrier. The coin remains a central focus of speculative discussions as the broader meme sector searches for renewed volume and momentum during ongoing market volatility.

The White Alien has arrived. The countdown to domination starts now.

The White Alien

The White Alien is generating significant social media momentum as investors link the asset to trending community narratives and cross-promote it alongside other speculative digital tokens. Market participants are actively engaging with the coin's viral persona, fueling discussions centered on community-driven growth and high-volatility momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is doubling down on its mission to revolutionize cancer treatment with radiation therapy. In just a few short weeks, the company has achieved a series of notable milestones, from a promising Phase 2 trial update to the appointment of veteran biotech executive George Scorsis as Chairman of the Board.With its lead candidate Ropidoxuridine already making waves in glioblastoma trials, Shuttle Pharma is positioning itself at the forefront of oncology innovation. The moves come as Shuttle looks to emulate recent breakthroughs by industry leaders such as <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/lantheus-holdings/">Lantheus Holdings (NASDAQ: LNTH)</a> and <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/novartis/">Novartis (NYSE: NVS)</a>, both of which have brought radiopharmaceutical therapies to market using similar underlying science.<h3>George Scorsis Steps In as Chairman</h3>On Wednesday, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">Shuttle Pharma announced</a> George Scorsis as the new Chairman of its Board of Directors. Scorsis brings over 25 years of executive experience, particularly in highly regulated sectors including biotech and cannabis. His resume includes leadership roles at Liberty Health Sciences and Mettrum Health Corp., and he currently chairs both <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/awakn-life-sciences">Awakn Life Sciences (CSE: AWKN) (OTCQB: AWKNF)</a> and Entourage Health Corp.Commenting on <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">his new role</a> at Shuttle, Scorsis stated:<blockquote>I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.</blockquote>Scorsis also previously served as Chairman of <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/sol-global-investments">SOL Global Investments (CSE: SOL) (OTC: SOLCF)</a>, which further illustrates his deep involvement in pioneering healthcare ventures.His appointment reflects Shuttle’s strategic push to strengthen its leadership team as it enters a pivotal period of clinical and commercial development.<h3>Ropidoxuridine Phase 2 Trial Gains Momentum</h3>The heart of Shuttle Pharma’s pipeline is <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/therapeutics/ropidoxuridine/">Ropidoxuridine</a> (IPdR), a novel radiation sensitizer currently in Phase 2 clinical trials for the treatment of glioblastoma. The aggressive brain cancer has limited treatment options and remains incurable. Shuttle’s approach aims to amplify the efficacy of radiation therapy while keeping side effects minimal.As of <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">May 8, 2025</a>, nearly 50% of the trial’s initial enrollment target had been met. Impressively, 84% of patients enrolled had completed all seven cycles of treatment. Trial sites—ranging from Georgetown University Medical Center to the Miami Cancer Institute—reported the drug was well tolerated, with toxicity scores not exceeding 2 on a 1-5 scale.Dr. Anatoly Dritschilo, who recently stepped down as Chairman and Chief Scientific Officer, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">said</a>, “If approved, we believe that Ropidoxuridine has the potential to redefine the standard approach for how to care for patients with glioblastoma.”Patients are being randomized into two dose cohorts—1,200 mg/day and 960 mg/day—to determine the optimal regimen. Once identified, an additional 14 patients will be enrolled at the best dose to reach statistical significance. The trial aims to complete enrollment later this year, with data readouts expected in 2026.Chris Cooper, Shuttle’s interim CEO, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">commented</a>:<blockquote>With nearly 50% of patient enrollment achieved in the initial randomized portion and 84% of enrolled patients completing all seven cycles, the trial is advancing steadily at esteemed cancer centers. Ropidoxuridine has been well-tolerated and we have begun analyzing pharmacokinetic and pharmacodynamic samples to optimize dosing and response. Our goal is to complete enrollment later this year, with follow-up and data readouts anticipated in 2026.</blockquote>The U.S. FDA has granted Orphan Drug Designation to Ropidoxuridine, giving Shuttle potential marketing exclusivity if approved. Given that an estimated 800,000 U.S. cancer patients undergo radiation therapy annually—and 400,000 of those for curative purposes—Shuttle’s target market is sizable and growing.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/5-minute-deep-dive-scorecard-is-shuttle-pharmaceuticals-nasdaq-shph-ready-for-a-massive-breakout/">5-Minute Deep Dive Scorecard: Is Shuttle Pharmaceuticals (NASDAQ: SHPH) Ready for a Massive Breakout?</a><h3>Innovation Extends Beyond the Clinic</h3>On May 15, 2025, Shuttle released a <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">corporate update</a> highlighting the company’s many recent developments. In addition to clinical progress, Shuttle has made strides in the diagnostics space. The company entered a sponsored research agreement with the University of California, San Francisco (UCSF) to develop a PSMA-targeted ligand for theranostic use in prostate cancer.Furthermore, Shuttle filed a <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-targets-prostate-cancer-with-psma-ligand-breakthrough/">provisional patent</a> titled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.” The filing was developed with Dr. Alan Kozikowski, a medicinal chemist whose past work helped enable the development of Lantheus’ Pylarify and Novartis’ Pluvicto—two commercially successful radiopharmaceuticals.Shuttle’s recent underwritten <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-closes-5-75-million-offering/">public offering</a> helped solidify its financial footing, with $4.5 million in cash and equivalents reported as of March 31, 2025. That cash will fund both the ongoing clinical trial and preclinical research efforts.<h3>Strengthened Leadership Amid Key Transitions</h3>While Scorsis’ arrival marks a new chapter, Shuttle has also seen notable exits. Dr. Dritschilo resigned from the Board and his role as CSO, while Michael Vander Hoek, the company’s VP of Regulatory, announced his retirement effective June 10.New board members Oleh Nabyt and Joseph Tung join Scorsis in reinforcing Shuttle’s governance and bringing expanded business and legal acumen to the table.<h3>Looking Ahead</h3>Shuttle Pharmaceuticals appears to be building momentum across multiple fronts—clinical, intellectual property, diagnostics, and leadership. With a new Chairman in place, promising mid-trial results, and a strengthened pipeline backed by a scientific pedigree, the company is drawing comparisons to past success stories, such as Lantheus Holdings and Novartis.Investors will watch closely as the Ropidoxuridine trial progresses toward full enrollment and data publication in 2026. If Shuttle can successfully deliver on its ambitions, it could play a major role in transforming radiation therapy for cancer patients worldwide.Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/videos/shuttle-pharma-showcases-cancer-treatment-advancements-at-planet-microcap-vegas-2025/">This Biotech Stock Took The Center Stage at the Planet MicroCap Showcase: VEGAS 2025</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:invest@wealthyvc.com">invest@wealthyvc.com</a>.This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>

Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations

Others

George Scorsis takes helm as Chairman as Ropidoxuridine trial nears 50% enrollment and patent advances boost pipeline.

SOL Global Investments Corp. is an investment company, which engages in the small and mid-cap sectors. It operates through the following segments : Retail, Agriculture, Technology, Esports and Gaming, Cryptocurrency, and New Age Wellness. The firm focuses on cannabis industry in legal U.S. states. Its objective is to provide shareholders with a long term return through capital appreciation, dividends and interest from its investments and has also made investments in the beverage and e-gaming industries. The company was founded by Jonathan Gilbert on January 28, 2005 and is headquartered in Toronto, Canada.

Current Price	$0.0456
Prev Close	$0.04
Open	$0.028
Dividend Yield	N/A
50-Day Moving Average	$0.0529
Beta	1.96
Avg. Volume	4,456.73
PE Ratio	-0.01

52-Week High	$1.20
52-Week Low	$0.019
Market Capitalization	$1.05M
EPS (Annual)	N/A
Price to Book	2.21
Revenue Per Employee	N/A

SOLCF
SOL Global Investments Corp

Feed

News

Sentiment

Fundamentals

Info

Latest SOLCF News

SOLCFSOL Global Investments Corp